<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079286</url>
  </required_header>
  <id_info>
    <org_study_id>AMCmedonc09/039</org_study_id>
    <nct_id>NCT01079286</nct_id>
  </id_info>
  <brief_title>Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers</brief_title>
  <acronym>I-NET</acronym>
  <official_title>Phase I Study of Nelfinavir in Combination With Temsirolimus in the Treatment of Patients With Advanced Cancers, Including Second Line Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study the investigators want to explore the safety, pharmacokinetics, and&#xD;
      activity of the combination of temsirolimus and nelfinavir, both agents with PI3K /Akt/mTOR&#xD;
      inhibiting activity, in patients with advanced malignancies.Temsirolimus has proven anti&#xD;
      tumoral activity by mTOR inhibition. Nelfinavir is a potential inhibitor of Akt. Combining&#xD;
      both agents might prevent upregulation of the P13k pathway and increase the anti-cancer&#xD;
      activity of temsirolimus. The strong CYP3A4 inhibition of nelfinavir and the dependence of&#xD;
      temsirolimus on CYP3 A4 metabolism makes a dose finding study essential. The investigators&#xD;
      will also look at the prospective value of biomarkers of activity and the outcome of the&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the past decade, the characterization of human tumours at the molecular level has&#xD;
      considerably improved. This has led to the development of targeted therapeutics that inhibit&#xD;
      specific molecules and pathways involved in oncogenesis. One of the key pathways that is&#xD;
      dysregulated in cancer is the phosphatidylinositol 3'-kinase (PI3K)/Akt/mTOR pathway. This&#xD;
      pathway is important for cell growth and survival. In most cancer types this pathway is&#xD;
      over-activated leading to proliferation and survival of malignant cells. Inhibition of this&#xD;
      pathway is therefore of great therapeutic potential.&#xD;
&#xD;
      Both temsirolimus and nelfinavir are agents with PI3K /Akt/mTOR inhibiting activity. The main&#xD;
      active metabolite of temsirolimus is sirolimus that decreases mTOR activity. Inhibition of&#xD;
      mTOR activity results in G1 phase cell cycle arrest and subsequent inhibition of tumour&#xD;
      growth. Another effect is growth factor downregulation and inhibition of angiogenesis. In&#xD;
      addition, mTOR inhibition may exert its anti-tumour effect by inducing apoptosis.&#xD;
&#xD;
      Although inhibitors of mTOR demonstrated clinical activity in tumor types like, mantle cell&#xD;
      lymphoma, endometrial carcinoma, and neuro-endocrine tumors, most malignancies are resistant&#xD;
      by feedback PI3 kinase activation. Resent data suggest that this tumor escape mechanism can&#xD;
      be overcome by dual inhibition of mTOR and PI3 kinase.&#xD;
&#xD;
      Nelfinavir is a well known human immuno-deficiency protease inhibitor with PI3kinase&#xD;
      inhibiting activity, via inhibition of Akt, downstream the PI3kinase cascade. Nelfinavir is&#xD;
      able to inhibit Akt at concentrations that are achieved in HIV patients at standard antiviral&#xD;
      doses. Nelfinavir is therefore a feasable and generally well tolerated agent to be used in&#xD;
      combination with temsirolimus to overcome resistance of mTOR inhibition.&#xD;
&#xD;
      Simultaneous inhibition of mTOR/PI3kinase pathway by temsirolimus and nelfinavir is a&#xD;
      promising strategy to treat cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics/pharmacodynamics</measure>
    <time_frame>During the first 5 weeks of treatment</time_frame>
    <description>PK Nelfinavir: D1, 11, 18, 25, 32 PK Temsirolimus: D4, 11, 18, 25,32</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>Day1 -Day90</time_frame>
    <description>Collection of clinical data according to CTC toxicity criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response to treatment</measure>
    <time_frame>Expected treatment duration: 2-12 months</time_frame>
    <description>Progress-scans once every 9 weeks will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description and change of Biomarker analysis/Pharmacodynamics</measure>
    <time_frame>Day 1, 18, 25</time_frame>
    <description>Blood biomarker analysis will be performed of PBMCs and where possible of tumor biposies performed during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetics</measure>
    <time_frame>day 1 of treatment</time_frame>
    <description>Full blood sample will be collected for pharmacogenetic analysis of important SNPs of drug disposition genes involved in the drug disposition of Nelfinivar and temsirolimus</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Renal Cell Cancer</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>nelfinavir and temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir and temsirolimus</intervention_name>
    <description>Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule</description>
    <arm_group_label>nelfinavir and temsirolimus</arm_group_label>
    <other_name>nelfinavir: viracept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histological or cytological confirmed malignancies&#xD;
&#xD;
          -  ECOG / WHO performance status of 0-2&#xD;
&#xD;
          -  Age 18 years&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Minimal acceptable safety laboratory values defined as&#xD;
&#xD;
          -  WBC 3.0 x 109 /L&#xD;
&#xD;
          -  Platelet count 100 x 109 /L&#xD;
&#xD;
          -  Hepatic function as defined by serum bilirubin 1.5 x ULN, ALT or AST 2.5 x ULN, in&#xD;
             case of liver metastases 5 x ULN&#xD;
&#xD;
          -  Renal function as defined by creatinine &lt; 150Î¼mol/L&#xD;
&#xD;
          -  Able and willing to give written informed consent according to ICH/GCP, and&#xD;
             national/local regulations.&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  Able and willing to undergo blood sampling for pharmacokinetic and pharmacogenetic&#xD;
             analysis&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known alcoholism, drug addiction and/or psychotic disorders in the&#xD;
             history that are not suitable for adequate follow up&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Women of childbearing potential who refuse to use a reliable contraceptive method&#xD;
             throughout the study&#xD;
&#xD;
          -  Serious concomitant systemic disorder that would compromise the safety of the patient,&#xD;
             at the discretion of the investigator&#xD;
&#xD;
          -  Any other medical condition that would interfere with study procedures and/or decrease&#xD;
             safety of the protocol treatment&#xD;
&#xD;
          -  Concomitant use of strong CYP3A4 inhibitors, CYP3A4 inducers or CYP substrates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz-Josef Klumpen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Heinz-Josef Klumpen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>mTOR inhibition</keyword>
  <keyword>advanced malignancies</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Akt inhibition</keyword>
  <keyword>Advanced malignancies, including metastatic renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

